TY - JOUR
T1 - In vitro activity of clinafloxacin in comparison with other quinolones against Stenotrophomonas maltophilia clinical isolates in the presence and absence of reserpine
AU - Ribera, Anna
AU - Jurado, Angels
AU - Ruiz, Joaquim
AU - Marco, Francesc
AU - Del Valle, Oscar
AU - Mensa, Josep
AU - Chaves, Josep
AU - Hernández, Gonzalo
AU - Jiménez de Anta, M. Teresa
AU - Vila, Jordi
N1 - Funding Information:
This study was supported by grants from Parke-Davis, Barcelona, Spain and Fondo de Investigaciones sanitarias (FIS 00/0632 and 00/0997), Spain. A.R. has a fellowship from the Ministerio de Educación y Ciencia, Spain.
PY - 2002
Y1 - 2002
N2 - A total of 33 Stenotrophomonas maltophilia clinical isolates were tested for their susceptibility to clinafloxacin in comparison with ciprofloxacin, levofloxacin, moxifloxacin, nalidixic acid, norfloxacin, sparfloxacin and trovafloxacin. The MIC50 and MIC90 were as follows: ciprofloxacin 4 and 64 μg/mL; clinafoxacin 0.5 and 4 μg/mL; levofloxacin 2 and 32 μg/mL; moxifloxacin 1 and 8 μg/mL; nalidixic acid 8 and 128 μg/mL; norfloxacin 64 and 256 μg/mL; sparfloxacin 1 and 16 μg/mL; and trovafloxacin 1 and 8 μg/mL. Clinafloxacin was the most active quinolone, with only a 15.1% of strains showing resistance. When the MICs were determined in the presence of 25 μg/ml of reserpine, the MIC90 of trovafloxacin and moxifloxacin did not change, whereas decreased 2-fold for clinafloxacin, levofloxacin, sparfloxacin and nalidixic acid, and 4- and 8-fold for ciprofloxacin and norfloxacin respectively. No clinafloxacin-resistant strains were observed when the MIC was performed in the presence of reserpine. Therefore, clinafloxacin shows the better "in vitro"activity against these 33 strains of S.maltophilia.
AB - A total of 33 Stenotrophomonas maltophilia clinical isolates were tested for their susceptibility to clinafloxacin in comparison with ciprofloxacin, levofloxacin, moxifloxacin, nalidixic acid, norfloxacin, sparfloxacin and trovafloxacin. The MIC50 and MIC90 were as follows: ciprofloxacin 4 and 64 μg/mL; clinafoxacin 0.5 and 4 μg/mL; levofloxacin 2 and 32 μg/mL; moxifloxacin 1 and 8 μg/mL; nalidixic acid 8 and 128 μg/mL; norfloxacin 64 and 256 μg/mL; sparfloxacin 1 and 16 μg/mL; and trovafloxacin 1 and 8 μg/mL. Clinafloxacin was the most active quinolone, with only a 15.1% of strains showing resistance. When the MICs were determined in the presence of 25 μg/ml of reserpine, the MIC90 of trovafloxacin and moxifloxacin did not change, whereas decreased 2-fold for clinafloxacin, levofloxacin, sparfloxacin and nalidixic acid, and 4- and 8-fold for ciprofloxacin and norfloxacin respectively. No clinafloxacin-resistant strains were observed when the MIC was performed in the presence of reserpine. Therefore, clinafloxacin shows the better "in vitro"activity against these 33 strains of S.maltophilia.
UR - http://www.scopus.com/inward/record.url?scp=0036178802&partnerID=8YFLogxK
U2 - 10.1016/S0732-8893(01)00335-2
DO - 10.1016/S0732-8893(01)00335-2
M3 - Artículo
C2 - 11858908
AN - SCOPUS:0036178802
SN - 0732-8893
VL - 42
SP - 123
EP - 128
JO - Diagnostic Microbiology and Infectious Disease
JF - Diagnostic Microbiology and Infectious Disease
IS - 2
ER -